Oncolys BioPharma and Chugai Pharmaceuticals agree to Terminate Exclusive License Agreement on Oncolytic Viral Immunotherapy, OBP-301(Telomelysin)
Keypoints: Chugai, Oncolys BioPharma agree to terminate exclusive license agreement on oncolytic viral immunotherapy, OBP-301 The effective date of the termination will…